Systemic capillary leak syndrome in a patient treated with nivolumab/ipilimumab immunotherapy for metastatic melanoma with concurrent COVID-19 vaccination.

Publication date: Jul 11, 2024

Systemic capillary leak syndrome (SCLS) is a rare and life-threatening disorder characterised by leaking of intravascular fluid to extravascular tissues. An association with immunotherapy and COVID-19 vaccination has been reported as potential triggers. A case of a patient in her 70s developing SCLS after the BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination with a history of metastatic melanoma treated with nivolumab (PD-1 monoclonal antibody) and ipilimumab (anti-CTLA4 monoclonal antibody) is reported. The aetiology and management of SCLS are also reviewed in this case context.

Concepts	Keywords
70s	Aged
Ctla4	Antineoplastic Agents, Immunological
Immunotherapy	Antineoplastic Agents, Immunological
Leak	BNT162 Vaccine
Vaccination	BNT162 Vaccine
	Capillary Leak Syndrome
	COVID-19
	COVID-19
	COVID-19 Vaccines
	COVID-19 Vaccines
	Female
	Humans
	Immunotherapy
	Ipilimumab
	Ipilimumab
	Melanoma
	Nivolumab
	Nivolumab
	SARS-CoV-2
	skin cancer
	Skin Neoplasms
	vaccination/immunisation

Semantics

Type	Source	Name
disease	MESH	Systemic capillary leak syndrome
drug	DRUGBANK	Nivolumab
drug	DRUGBANK	Ipilimumab
disease	MESH	melanoma
pathway	KEGG	Melanoma
disease	MESH	COVID-19
disease	VO	vaccination
disease	IDO	history
disease	VO	vaccine
disease	MESH	skin cancer

Original Article

(Visited 3 times, 1 visits today)